Share & Earn

Althealth

Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections

0 3 years ago

BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /CNW/ — Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

“Bugworks represents one of four CARB-X programs conducting First-in-Human trials this year,” said CARB-X Chief of R&D Dr. Erin Duffy. “We are proud to have accelerated this program from a Lead Optimization campaign through to this study to demonstrate safety and drug levels in healthy humans. ‘0977 has the potential to cover a broad range of priority pathogens in the syndromes of high unmet need.”

BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration, for the treatment of serious multi drug resistant (MDR) Gram-negative infections such as Acinetobacter baumannii, Pseudomonas aeruginosa, carbapenemase producing Enterobacteriaceae, and drug resistant Gram-positive infections such as methicillin resistant staphylococci (MRSA), vancomycin resistant enterococci (VRE) and penicillin resistant streptococci (PRSP). BWC0977 can address many serious hospital & community infections and combat a broad spectrum of biothreat pathogens. It has the potential of becoming a breakthrough antibiotic, not seen since the 1960’s.

READ FULL ARTICLE

Leave a Comment

Your email address will not be published. Required fields are marked *